BNC Korea Co., Ltd. (256840.KQ)
KRW 4160.0
(-1.42%)
KRW 4160.0
(-1.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 14.17 Billion KRW | 384.02% |
| 2022 | -38.84 Billion KRW | 39.81% |
| 2021 | -220.58 Billion KRW | -395.88% |
| 2020 | 2.22 Billion KRW | -19.67% |
| 2019 | -4.05 Billion KRW | -33.55% |
| 2018 | 4.57 Billion KRW | 12530.44% |
| 2017 | -42.23 Million KRW | -151.77% |
| 2016 | -16.77 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 6.71 Billion KRW | 105.09% |
| 2024 Q1 | 3.28 Billion KRW | 3.05% |
| 2023 FY | - KRW | 384.02% |
| 2023 Q3 | 5.72 Billion KRW | -0.88% |
| 2023 Q4 | 3.17 Billion KRW | -44.46% |
| 2023 Q1 | -497.51 Million KRW | 40.23% |
| 2023 Q2 | 5.77 Billion KRW | 1260.02% |
| 2022 Q2 | -2.09 Billion KRW | -60.74% |
| 2022 FY | - KRW | 39.81% |
| 2022 Q4 | -832.45 Million KRW | 5.91% |
| 2022 Q3 | -884.77 Million KRW | 57.73% |
| 2022 Q1 | -1.3 Billion KRW | 33.85% |
| 2021 FY | - KRW | -395.88% |
| 2021 Q3 | -866.07 Million KRW | 0.0% |
| 2021 Q4 | -1.96 Billion KRW | -127.26% |
| 2020 FY | - KRW | -19.67% |
| 2019 FY | - KRW | -33.55% |
| 2018 FY | - KRW | 12530.44% |
| 2017 FY | - KRW | -151.77% |
| 2016 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -2338.777% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -153.311% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 73.865% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 90.672% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 84.021% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 345.449% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 74.175% |
| Boditech Med Inc. | 36.48 Billion KRW | 61.162% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 422.679% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 2496.845% |
| Huons Co., Ltd. | 74.23 Billion KRW | 80.909% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 208.973% |